首页> 美国卫生研究院文献>EFSA Journal >Bifidobacterium animalis subsp. lactis Bi‐07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
【2h】

Bifidobacterium animalis subsp. lactis Bi‐07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

机译:双歧杆菌蛛网潜水管。 Lactis Bi-07有助于增加乳糖消化:根据第13(5)条第13(5)条第1924/2006条的第13(5)条评估健康索赔

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Following an application from DuPont Nutrition Biosciences ApS submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi‐07 (Bi‐07) and contribution to increasing lactose digestion. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Bi‐07. The Panel considers that Bi‐07 is sufficiently characterised. The claimed effect proposed by the applicant is ‘improvement of lactose digestion’. The Panel considers that increasing lactose digestion is a beneficial physiological effect for individuals with lactose maldigestion provided that the symptoms of lactose maldigestion are improved. Two human intervention studies which investigated a single dose effect of Bi‐07 on lactose digestion using the hydrogen breath test, as well as on gastrointestinal symptoms were submitted. These studies show that consumption of Bi‐07 (1012CFU) increases lactose digestion in individuals with lactose maldigestion and that Bi‐07 exhibits lactase activity in vitro. However, these studies provide no evidence that increasing lactose digestion through the consumption of Bi‐07 (1012CFU) improves gastrointestinal symptoms of lactose maldigestion, which is considered a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bifidobacterium animalis subsp. lactis Bi‐07 and a beneficial physiological effect (i.e. the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.
机译:遵循杜邦营养生物科学的申请,提交授权健康索赔的批准,根据第13(5)条通过IFSA营养,新鲜食品和食品过敏原授权于1924/2006年第1924/2006条第1924/2006款(EFSA小组)(要求NDA)有关与双歧双歧杆菌患者有关的健康索赔的科学证实的意见。 Lactis Bi-07(Bi-07)和对增加乳糖消化的贡献。申请的范围是根据新制定的科学证据的健康索赔下降。申请人作为健康索赔主题提出的食品是BI-07。面板认为Bi-07的特征是。申请人提出的索赔效果是“改善乳糖消化”。小组认为,增加乳糖消化是乳糖混乱的个体的有益生理效果,条件是乳糖混合物的症状得到改善。使用氢气呼气试验研究了两种人类干预研究,研究了BI-07对乳糖消化的单剂量效应,以及提交胃肠症状。这些研究表明,消耗BI-07(1012CFU)增加了乳糖混合物中的个体中的乳糖消化,并且BI-07在体外表现出乳糖酶活性。然而,这些研究没有证据表明通过BI-07的消费增加乳糖消化(1012CFU)改善了乳糖症状的胃肠道症状,被认为是有益的生理效应。小组得出结论,术语双歧杆菌消毒剂消耗之间没有建立了原因和效应关系。 Lactis Bi-07和有益的生理效果(即乳糖混合物的个体中的乳糖症状的改善)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号